SAN FRANCISCO Sept. 8 2011 PRNewswire Nektar Therapeutics Nasdaq NKTR today announced that dosing began in a Phase 1 clinical study to evaluate multiple ascending doses of NKTR181 the company's novel opioid analgesic drug candidate. NKTR181 is in developm...
↧